Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effect of bezafibrate on cholestatic itch

Next Previous
Trial Profile

The effect of bezafibrate on cholestatic itch

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bezafibrate (Primary)
  • Indications Cholestasis; Pruritus
  • Focus Therapeutic Use
  • Acronyms FITCH

Most Recent Events

  • 05 Oct 2020 Primary endpoint, Proportion of patients reaching a 50% or more reduction in itch intensity VAS score after 21 days of treatment has been met as per results published in the Gastroenterology
  • 05 Oct 2020 Results published in the Gastroenterology
  • 13 Jan 2020 This trial has been completed in Spain, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top